









市場行情
/
股票
/
nasdaq-autl
/

Autolus Therapeutics PLC

AUTL

1.640USD

-0.090-5.20%

收盤 12/23, 16:00（美東）報價延遲15分鐘

436.47M總市值

虧損本益比TTM



Autolus Therapeutics PLC

1.640

-0.090-5.20%

概覽公司財務分析

概覽

公司

財務

分析

關於 Autolus Therapeutics PLC 公司

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Autolus Therapeutics PLC簡介



公司代碼AUTL

公司名稱Autolus Therapeutics PLC

上市日期Jun 22, 2018

CEOItin (Christian Martin)

員工數量647

證券類型Depository Receipt

年結日Jun 22

公司地址The Mediaworks

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編W12 7FP

電話442038296230

網址https://www.autolus.com/

公司代碼AUTL

上市日期Jun 22, 2018

CEOItin (Christian Martin)

Autolus Therapeutics PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Cynthia M. Butitta

Non-Executive Independent Director

10.00K

Mr. Brent Rice

Senior Vice President, Chief Commercial Officer

9.40K

Mr. Christopher Vann

Chief Operating Officer, Senior Vice President

Mr. Robert (Rob) Dolski

Chief Financial Officer, Senior Vice President

Dr. Christian Martin Itin, Ph.D.

Chief Executive Officer, Executive Director

Mr. Michael W. (Mike) Bonney

Chairman of the Board

Mr. John Edward Berriman

Non-Executive Independent Director

Mr. William D. (Bill) Young, Ph.D.

Non-Executive Independent Director

Mr. David Brochu

Senior Vice President, Chief Technical Officer

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Ms. Cynthia M. Butitta

Non-Executive Independent Director

10.00K

Mr. Brent Rice

Senior Vice President, Chief Commercial Officer

9.40K

Mr. Christopher Vann

Chief Operating Officer, Senior Vice President

Mr. Robert (Rob) Dolski

Chief Financial Officer, Senior Vice President

Dr. Christian Martin Itin, Ph.D.

Chief Executive Officer, Executive Director

Mr. Michael W. (Mike) Bonney

Chairman of the Board

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

20.92M

100.00%

United Kingdom

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月2日週二

持股股東

股東類型

持股股東

佔比

Syncona Investment Management Limited

11.55%

MAK Capital One, LLC

10.10%

Clarus Ventures, LLC

7.70%

Syncona Portfolio Ltd

6.25%

Armistice Capital LLC

5.86%

其他

58.54%

持股股東

佔比

Syncona Investment Management Limited

11.55%

MAK Capital One, LLC

10.10%

Clarus Ventures, LLC

7.70%

Syncona Portfolio Ltd

6.25%

Armistice Capital LLC

5.86%

其他

58.54%

股東類型

持股股東

佔比

Hedge Fund

23.57%

Investment Advisor

23.48%

Corporation

12.52%

Investment Advisor/Hedge Fund

9.14%

Venture Capital

8.06%

Sovereign Wealth Fund

5.64%

Holding Company

5.55%

Research Firm

1.83%

Private Equity

1.74%

其他

8.47%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

230

194.47M

90.55%

+128.60K

2025Q3

237

202.34M

94.14%

-20.86M

2025Q2

235

223.88M

91.00%

-2.80M

2025Q1

228

230.12M

90.84%

-11.63M

2024Q4

235

229.60M

92.37%

-10.27M

2024Q3

225

234.01M

89.22%

+30.38M

2024Q2

227

202.70M

79.95%

+2.45M

2024Q1

217

200.05M

58.18%

+45.35M

2023Q4

191

140.21M

76.10%

+4.14M

2023Q3

169

139.76M

70.07%

+377.17K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Syncona Investment Management Limited

30.73M

11.55%

+30.73M

Sep 30, 2024

MAK Capital One, LLC

16.96M

6.37%

+16.96M

Jun 30, 2025

Clarus Ventures, LLC

20.49M

7.7%

Jun 30, 2025

Syncona Portfolio Ltd

16.64M

6.25%

Jun 30, 2025

Armistice Capital LLC

12.00M

4.51%

+1.00M

+9.09%

Jun 30, 2025

Qatar Investment Authority

15.00M

5.64%

Mar 01, 2025

PPF Group N.V.

14.78M

5.55%

+170.00K

+1.16%

Oct 24, 2024

Polygon Management Ltd.

9.50M

3.57%

+900.00K

+10.47%

Jun 30, 2025

Schroder Investment Management Ltd. (SIM)

3.61M

1.36%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.56%

Virtus LifeSci Biotech Clinical Trials ETF

0.49%

ALPS Medical Breakthroughs ETF

0.17%

iShares Health Innovation Active ETF

0.07%

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

iShares Biotechnology ETF

0.02%

SPDR S&P International Small Cap ETF

0.01%

Tema Oncology ETF

Fidelity Fundamental Small-Mid Cap ETF

Invesco NASDAQ Future Gen 200 ETF

佔比0.56%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.49%

ALPS Medical Breakthroughs ETF

佔比0.17%

iShares Health Innovation Active ETF

佔比0.07%

ProShares Ultra Nasdaq Biotechnology

佔比0.03%

Invesco Nasdaq Biotechnology ETF

佔比0.03%

iShares Biotechnology ETF

佔比0.02%

SPDR S&P International Small Cap ETF

佔比0.01%

Tema Oncology ETF

佔比0%

Fidelity Fundamental Small-Mid Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Autolus Therapeutics PLC的前五大股東是誰？



Autolus Therapeutics PLC的前五大股東如下：
Syncona Investment Management Limited
持有股份：30.73M
佔總股份比例：11.55%。
MAK Capital One, LLC
持有股份：16.96M
佔總股份比例：6.37%。
Clarus Ventures, LLC
持有股份：20.49M
佔總股份比例：7.70%。
Syncona Portfolio Ltd
持有股份：16.64M
佔總股份比例：6.25%。
Armistice Capital LLC
持有股份：12.00M
佔總股份比例：4.51%。